Peptide therapies have gained significant traction in veterinary medicine over the past several years. Veterinarians across the United States report using compounds like BPC-157 for equine tendon injuries and canine joint recovery, while growth hormone-releasing peptides have appeared in large-animal practice. But the legal landscape governing veterinary peptide use is fragmented, overlapping, and in many cases poorly understood — even by practitioners.
This article breaks down the federal and state regulatory framework that determines when and how peptides may legally be used in animal patients.
FDA Animal Drug Regulation: The Basics
The FDA's Center for Veterinary Medicine (CVM) oversees the approval and regulation of drugs used in animals. Under the Federal Food, Drug, and Cosmetic Act (FD&C Act), any substance intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in animals is considered an animal drug and must be FDA-approved or index-listed before it can be legally marketed.
Most peptides used in veterinary practice are not FDA-approved animal drugs. This creates a legal gray area. Unlike human medicine — where compounding pharmacies operate under 503A and 503B frameworks — veterinary compounding follows a different set of rules governed by CVM's Compliance Policy Guide (CPG) 608.400.
Under CPG 608.400, the FDA exercises enforcement discretion regarding compounded animal drugs, provided certain conditions are met:
- The compounded product is prescribed by a licensed veterinarian within a valid veterinarian-client-patient relationship (VCPR)
- There is no FDA-approved animal drug that can treat the condition in the species being treated
- The compounding is performed by a licensed pharmacist or veterinarian
- The compounded product does not present a safety risk to the animal, the public, or the food supply
Extra-Label Drug Use and AMDUCA
The Animal Medicinal Drug Use Clarification Act (AMDUCA), enacted in 1994, is the primary federal statute authorizing extra-label drug use in animals. AMDUCA permits veterinarians to prescribe FDA-approved human or animal drugs for uses not specified on the label — a practice known as extra-label use — under specific conditions.
For AMDUCA to apply, the following criteria must be met:
- A valid veterinarian-client-patient relationship (VCPR) exists
- The veterinarian has determined that the animal's health is threatened or that suffering or death may result without treatment
- There is no FDA-approved animal drug that is labeled for the specific use and that is clinically effective
- The veterinarian has made a careful medical judgment about the appropriateness of the drug
- Appropriate withdrawal times are established for food-producing animals
AMDUCA provides a legal pathway for veterinarians to use FDA-approved drugs in extra-label fashion. However, it does not authorize the use of unapproved bulk drug substances. This distinction is critical for peptides: if a peptide is not an FDA-approved drug (in either human or veterinary medicine), AMDUCA's extra-label provisions do not apply to it directly.
Which Peptides Are Veterinarians Using?
Despite the regulatory complexity, veterinary use of peptides has expanded considerably. Based on industry reports and veterinary conference proceedings, the most commonly used peptides in animal practice include:
| Peptide | Common Veterinary Applications | Species | FDA-Approved? |
|---|---|---|---|
| BPC-157 | Tendon/ligament injuries, gut healing, post-surgical recovery | Horses, dogs | No |
| TB-500 (Thymosin Beta-4) | Wound healing, tissue repair, inflammation | Horses, dogs | No |
| Pentosan Polysulfate (Adequan) | Osteoarthritis, joint disease | Horses, dogs | Yes (veterinary) |
| GnRH (Gonadorelin) | Reproductive management, ovulation induction | Cattle, horses | Yes (veterinary) |
| IPAMORELIN | Growth hormone release, age-related decline | Dogs | No |
Equine medicine has been a particularly active area. Racehorses and sport horses frequently receive peptide therapies for musculoskeletal injuries, and some equine veterinarians have reported favorable outcomes with BPC-157 and TB-500 in peer conference presentations.
DEA Considerations for Controlled Substance Peptides
Most peptides are not scheduled under the Controlled Substances Act (CSA) and therefore do not fall under DEA jurisdiction. However, there are important exceptions and emerging considerations:
- Growth hormone-releasing peptides: While not currently scheduled as controlled substances, some GH secretagogues have drawn scrutiny from anti-doping agencies and could face future scheduling if abuse patterns emerge
- Compounded controlled substances: If a veterinary compounding pharmacy combines a peptide with a DEA-scheduled substance (such as certain sedatives or analgesics), standard DEA requirements for controlled substance handling apply
- State-level scheduling: Some states have enacted their own controlled substance schedules that may classify certain peptides differently than federal law
Veterinarians should verify both federal and state scheduling status before administering or prescribing any peptide therapy.
State Veterinary Board Regulations
State veterinary practice acts and boards of veterinary medicine add another layer of regulation. Each state defines the scope of veterinary practice, the requirements for a valid VCPR, and the rules governing compounding and dispensing of drugs by veterinarians.
Key state-level variations include:
- VCPR requirements: Some states require an in-person examination before establishing a VCPR, while others have adopted telemedicine provisions
- Compounding authority: States differ on whether veterinarians themselves may compound medications in-office or must use a licensed pharmacy
- Record-keeping: Most states require detailed medical records for any drug administration, including off-label or compounded substances
- Food animal restrictions: States with significant agricultural industries may impose additional restrictions on drug use in food-producing animals to protect the food supply
Veterinarians using peptides should consult their state board's regulations and, when in doubt, seek guidance from veterinary legal counsel.
The Regulatory Gray Area
The fundamental challenge with veterinary peptide use is that most peptides occupy a regulatory gray area. They are not FDA-approved animal drugs, and many are not FDA-approved human drugs either. The FDA's enforcement discretion framework under CPG 608.400 provides some flexibility, but it is not a blanket authorization.
The FDA has signaled increased attention to unapproved animal drugs in recent years, particularly in the equine industry. Veterinarians relying on unapproved peptides should be aware that enforcement actions — while historically rare — are possible, especially if adverse events are reported or if products are marketed with therapeutic claims.
FAQ: Veterinary Peptide Legality
Can a veterinarian legally prescribe BPC-157 for my dog?
The legal status is complex. BPC-157 is not an FDA-approved drug for any species. While veterinarians have some latitude to use unapproved substances under enforcement discretion frameworks, prescribing BPC-157 carries regulatory risk. The veterinarian must have a valid VCPR and must exercise professional judgment that the treatment is appropriate. State veterinary board rules may also apply.
Are peptides tested for safety in animals?
Many peptides used in veterinary practice have been studied in animal models as part of preclinical research, but this is different from the controlled safety and efficacy testing required for FDA drug approval. Published animal studies may indicate potential benefits, but they do not establish regulatory approval for therapeutic use.
Do racing commissions regulate peptide use in horses?
Yes. State racing commissions maintain lists of prohibited and restricted substances for competition horses. Many peptides, including BPC-157, TB-500, and growth hormone secretagogues, are banned in competition by most racing jurisdictions. The Association of Racing Commissioners International (ARCI) publishes model rules that most states follow. Violations can result in fines, suspensions, and disqualification of race results.
Is it legal to buy peptides for animal research?
Peptides sold explicitly as research chemicals — labeled "not for human or veterinary use" — occupy a different regulatory space. Purchasing research-grade peptides for legitimate laboratory research on animals conducted under an institutional protocol is generally permissible. However, purchasing "research" peptides with the intent to administer them as therapeutic treatments to animals circumvents the drug approval framework and carries legal risk.
Sources and References
- FDA Center for Veterinary Medicine — Compliance Policy Guides
- AVMA — AMDUCA: Extra-Label Drug Use in Animals
- Congress.gov — Animal Medicinal Drug Use Clarification Act of 1994
- FDA — Compounding Animal Drugs from Bulk Drug Substances
- Association of Racing Commissioners International — Model Rules
This article is for educational and informational purposes only and does not constitute legal or veterinary advice. Laws and regulations vary by jurisdiction and are subject to change. Consult a qualified veterinarian and attorney for guidance specific to your situation.